MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

0.37 -11.9

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.36

Max

0.42

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+947.62% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-12M 94M
Eelmine avamishind	12.27
Eelmine sulgemishind	0.37

Uudiste sentiment

By Acuity

25%

75%

319 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. apr 2026, 23:27 UTC

Uudisväärsed sündmused

BHP Expects Annual Copper Output in Upper Half of Guidance, Finishes China Iron-Ore Negotiations

21. apr 2026, 23:27 UTC

Kuumad aktsiad

Stocks to Watch: Sonoco Products, Adobe, Manhattan Associates, Target Hospitality

21. apr 2026, 23:02 UTC

Tulu

Correction to Capital One Financial 1Q Earnings Article

21. apr 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. apr 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Hopes for U.S.-Iran Peace Talks Fade

21. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Market Talk Roundup: Latest on U.S. Politics

21. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher After Trump Says U.S. Will Extend Cease-Fire Deadline -- Market Talk

21. apr 2026, 23:32 UTC

Tulu

America Movil 1Q EBITDA MXN94.5B, Up 3.8% on Year >AMX

21. apr 2026, 23:30 UTC

Tulu

America Movil 1Q Rev MXN236.84B, Up 2.1% on Year >AMX

21. apr 2026, 23:28 UTC

Tulu

America Movil 1Q Net MXN23.4B Vs. Net MXN18.7B >AMX

21. apr 2026, 23:16 UTC

Uudisväärsed sündmused

Ampol Entered 2Q With Hedge Book Positioned to Mitigate Volatility

21. apr 2026, 23:15 UTC

Uudisväärsed sündmused

Ampol Entered 2Q With Broad-Based Momentum

21. apr 2026, 23:15 UTC

Uudisväärsed sündmused

Ampol: Suitable Crudes for Lytton Remain Available in Market

21. apr 2026, 23:14 UTC

Uudisväärsed sündmused

Ampol: Crude Supplies Secured Into July

21. apr 2026, 23:14 UTC

Uudisväärsed sündmused

Ampol: Fuel Supplies Secured Until at Least End of May

21. apr 2026, 23:13 UTC

Uudisväärsed sündmused

Ampol: Well Placed for Crude, Product Supply Prior to Iran Conflict

21. apr 2026, 23:13 UTC

Uudisväärsed sündmused

Ampol 1Q Lytton Refinery Production 1.43 Billion Liters

21. apr 2026, 23:12 UTC

Uudisväärsed sündmused

Ampol 1Q Lytton Refiner Margin US$25.45/Bbl

21. apr 2026, 22:54 UTC

Market Talk

Sell America Trade Could Gain Momentum If Fed Uncertainty Unresolved -- Market Talk

21. apr 2026, 22:49 UTC

Uudisväärsed sündmused

BHP 3Q Average Realized Energy Coal Price $105.61/Ton, Up 10% On-Quarter

21. apr 2026, 22:49 UTC

Uudisväärsed sündmused

BHP 3Q Average Realized Steelmaking Coal Price $226.76/Ton, Up 15% On-Quarter

21. apr 2026, 22:48 UTC

Uudisväärsed sündmused

BHP 3Q Average Realized Iron Ore Price $85.35/Ton, Flat On-Quarter

21. apr 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Alliance Portfolio Is Comprised of Five Plants: Batavia, Hillburn, Massena, Shoemaker and Sterling

21. apr 2026, 22:48 UTC

Uudisväärsed sündmused

BHP 3Q Average Realized Copper Price $5.86/Pound, Down 1% On-Quarter

21. apr 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

PowerTransitions to Buy 323 MW of Power Generation Assets in New York State From Alliance Energy Group

21. apr 2026, 22:46 UTC

Uudisväärsed sündmused

BHP: Has Concluded Iron Ore Sales Contract Negotiations With China Mineral Resources Group

21. apr 2026, 22:45 UTC

Uudisväärsed sündmused

BHP: Pampa Norte Production Down on Ore Complexity, Variation; Declining Grades

21. apr 2026, 22:45 UTC

Uudisväärsed sündmused

BHP: Escondida Concentrator Investment Estimated Between $4.4 Billion-$5.9 Billion

21. apr 2026, 22:44 UTC

Uudisväärsed sündmused

BHP: Escondida Concentrator Project Seen Facing FID in 2027-28

21. apr 2026, 22:42 UTC

Uudisväärsed sündmused

BHP CEO: Centralized Procurement, Low-cost Operations Help Buffer Industry Wide Cost Pressures

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

947.62% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 947.62%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

319 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.